Login / Signup

Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE).

Ai Phuong TranDaniel TassoneJohannes Cornelis NossentNik Sheng Ding
Published in: RMD open (2022)
ANZCTR: 12621000661875.
Keyphrases
  • coronavirus disease
  • sars cov
  • oxidative stress
  • stem cells
  • respiratory syndrome coronavirus
  • bone marrow
  • replacement therapy